Cyclomune
Developed to support ocular surface inflammation to alleviate dry eye symptoms.
- Categories
- Eye Care · Autoimmune Support
- Active ingredient
- Ciclosporin
- Supply
- Rx
- Route
- Ocular use
- Form
- Eye drops, emulsion
- Strengths
- 0.05 · 0.1%
Cyclomune details
- Condition
- Keratoconjunctivitis Sicca
- Alternative names
- Ikervis; Verkazia
- Therapeutic class
- Immunosuppressant
- Pharmacological class
- Calcineurin Inhibitor
- Contraindications
- active ocular infection
- Minor side effects
- ocular burning; conjunctival hyperaemia
- Moderate side effects
- epiphora; eye pain
- Serious side effects
- corneal ulceration, requires immediate medical attention
- Dosage forms
- Eye drops, emulsion
- Administration route
- Ocular use
- Patient summary
- developed to support ocular surface inflammation to alleviate dry eye symptoms.
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Sun Pharma
- Onset Time
- 4–8 weeks
- Duration
- Long-term
- Storage instructions
- Store in a cool, dry place.
- Age restrictions
- 18 years and over
- Pregnancy and breastfeeding
- Pregnancy: consult doctor. Breastfeeding: caution advised.
Precautions and warnings
remove contact lenses before application; use caution in patients with history of herpes keratitis
Mechanism of action
Acts as an immunomodulator by inhibiting T-lymphocyte activation, which helps reduce ocular inflammation.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Cyclomune
Cyclomune contains ciclosporin, a solution used to manage keratoconjunctivitis sicca. The same active ingredient is sold under other brand names including Ikervis and Verkazia, provided in a bottle with concentrations of 0.05% and 0.1%. Produced by Sun Pharma, this treatment addresses the underlying inflammation commonly associated with dry eye conditions.
Cyclomune availability in Asia
Cyclomune is registered across 13 markets, including Thailand, Malaysia and the Philippines, with availability also supported in Indonesia, Taiwan and South Korea. Generic ciclosporin, much of it manufactured in India, often offers a more accessible price point than original versions for patients located at a distance from a local pharmacy. As with all specialised ocular treatments, it is best used under a doctor’s care.